FLT3抑制通过FOXO上调HDAC8使p53失活并维持FLT3-ITD阳性急性髓系白血病
研究揭示FLT3-ITD阳性AML中FLT3抑制经FOXO1/3转录激活上调HDAC8,HDAC8使p53去乙酰化失活,导致白血病维持和TKI耐药。遗传或药理抑制HDAC8可重新激活p53并增强TKI清除原始FLT3-ITD阳性细胞,患者来源异种移植模型中AC220联合HDAC8抑制剂22d显著抑制白血病进展。
要点
- FLT3抑制通过FOXO1/3上调HDAC8,进而使p53去乙酰化失活。
- HDAC8抑制可重新激活p53并增强TKI对FLT3-ITD阳性AML细胞的清除。
- AC220联合22d在FLT3-ITD阳性AML PDX模型中显著抑制白血病进展。
核心结论
- HDAC8上调是FLT3-ITD阳性AML抵抗TKI和维持白血病的重要机制。
- 联合HDAC8抑制与TKI可能是治疗FLT3-ITD阳性AML及其他酪氨酸激酶突变白血病的 promising 策略。
研究设计与样本
- 研究采用FLT3-ITD阳性AML细胞及患者来源异种移植(PDX)模型进行机制与干预实验。
主要发现
- FLT3抑制通过FOXO1和FOXO3介导的反式激活诱导HDAC8上调。
- 上调的HDAC8使p53去乙酰化并失活,导致白血病维持和TKI治疗时的耐药。
- 遗传或药理抑制HDAC8可重新激活p53、消除白血病维持并显著增强TKI介导的FLT3-ITD阳性AML细胞清除。
- 在FLT3-ITD阳性AML PDX模型中,FLT3 TKI(AC220)联合HDAC8抑制剂(22d)显著抑制白血病进展并有效减少原始FLT3-ITD阳性AML细胞。
- 上述发现可扩展至携带另一种酪氨酸激酶激活突变的AML亚型。
临床怎么用
- 对FLT3-ITD阳性AML,可考虑在FLT3 TKI治疗基础上联合HDAC8抑制以增强清除原始白血病细胞。
- HDAC8抑制可能有助于克服FLT3 TKI耐药并减少复发来源。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Internal tandem duplication (ITD) mutations within the FMS-like receptor tyrosine kinase-3 (FLT3) can be found in up to 25% to 30% of acute myeloid leukemia (AML) patients and confer a poor prognosis. Although FLT3 tyrosine kinase inhibitors (TKIs) have shown clinical responses, they cannot eliminate primitive FLT3-ITD+ AML cells, which are potential sources of relapse. Therefore, elucidating the mechanisms underlying FLT3-ITD+ AML maintenance and drug resistance is essential to develop novel effective treatment strategies. Here, we demonstrate that FLT3 inhibition induces histone deacetylase 8 (HDAC8) upregulation through FOXO1- and FOXO3-mediated transactivation in FLT3-ITD+ AML cells. Upregulated HDAC8 deacetylates and inactivates p53, leading to leukemia maintenance and drug resistance upon TKI treatment. Genetic or pharmacological inhibition of HDAC8 reactivates p53, abrogates leukemia maintenance, and significantly enhances TKI-mediated elimination of FLT3-ITD+ AML cells. Importantly, in FLT3-ITD+ AML patient-derived xenograft models, the combination of FLT3 TKI (AC220) and an HDAC8 inhibitor (22d) significantly inhibits leukemia progression and effectively reduces primitive FLT3-ITD+ AML cells. Moreover, we extend these findings to an AML subtype harboring another tyrosine kinase-activating mutation. In conclusion, our study demonstrates that HDAC8 upregulation is an important mechanism to resist TKIs and promote leukemia maintenance and suggests that combining HDAC8 inhibition with TKI treatment could be a promising strategy to treat FLT3-ITD+ AML and other tyrosine kinase mutation-harboring leukemias.
引用
- Long J, Jia MY, Fang WY, et al. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia. Blood. 2020. PMID: 32315388. doi:10.1182/blood.2019003538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。